MHC class I-presented tumor antigen appraisable for T-cell responses against ovarian cancer

Authors

  • Jing Yao Wang Departmentof Gynecology, Second Hospital of Tianjin Medical University; Department of Gynaecology and Obstetrics, Tangshan Maternal and Children Health Hospital
  • Nan Zhang Department of Orthopedics, Tangshan Kailuan General Hospital, Tangshan 063 000
  • Xiaojie Yang Department of Gynecology and Obstetrics, Tangshan Maternal and Children Health Hospital, Tangshan 063 000
  • Danli Gao Department of Gynecology and Obstetrics, Tangshan Maternal and Children Health Hospital, Tangshan 063000
  • Lirong Yin Department of Gynecology, Second Hospital of Tianjin Medical University, Tianjin 300211
  • Shuying Ji Department of Gynecology and Obstetrics, Tangshan Maternal and Children Health Hospital, Tangshan 063 000

DOI:

https://doi.org/10.3329/bjp.v10i3.23076

Keywords:

MHC Class I, Ovarian cancer, T-Cell response, Tumor antigen

Abstract

The purpose of this study is to assess whether MHC class I-presented tumor antigen is appraisable for T-cell responses against ovarian cancer. In ovarian cancer cell, human leukocyte antigen A2 (HLA-A2) associated with peptides was used to promote the activation of naive T cells so as to activate antigen-specific T cells. 7 or 4 patients were observed grade 1 or 2 injection site reactions, respectively. 5, 2 or 1 patients were observed grade 1, 2 or 3 pain reactions, respectively. 4 or 1 patients were observed grade 1 or 2 induration reactions. Total number mean value of patients experiencing response to the particular peptide was 7.73, and total number mean value of peptides to which the patients responded was 7.45. MHC class I-presented tumor antigen is appraisable for T-cell responses against ovarian cancer in China.

Downloads

Download data is not yet available.
Abstract
298
Download
164 Read
135

References

Cao YH, Fan JW, Li AX, Liu HF, Li LR, Zhang CL, Zeng L, Sun ZZ. Identification of MHC I class genes in two Platyrrhini species. Am J Primatol. 2015, 10.1002/ajp.22372.

Catamo E, Zupin L, Crovella S, Celsi F, Segat L. Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma. Hum Immunol. 2014; 75: 1225-31.

Chen D, Gaborieau V, Zhao Y, Chabrier A, Wang H, Waterboer T, Zaridze D, Lissowska J, Rudnai P, Fabianova E, Bencko V, Janout V, Foretova L, Mates IN, Szeszenia-Dabrowska N, Boffetta P, Pawlita M, Lathrop M, Gyllensten U, Brennan P, McKay JD. A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity. Hum Mol Genet. 2015, 10.1093/hmg/ddv015.

Chen K, Wei H, Ling S, Yi C. Expression and significance of transforming growth factor-beta1 in epithelial ovarian cancer and its extracellular matrix. Oncol Lett. 2014; 8: 2171-74.

Chen LC, Lan H, Sun L, Deng YL, Tang KY, Wan QH. Genomic organization of the crested ibis MHC provides new insight into ancestral avian MHC structure. Sci Rep. 2015; 5: 7963.

Chen W, Cai MY, Wei DP, Wang X. Pivotal molecules of MHC I pathway in human primary hepatocellular carcinoma. World J Gastroenterol. 2005; 11: 3297-99.

Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol. 2013; 191: 1567-77.

Haimiti A, Hailiman Y, Gulina A, Du J, Hao Z, Rong XL, Zainuer A, Qin W, Lalai S. Reduced expression of members of the MHC-I antigen processing machinery in ethnic Uighur women with cervical cancer in the Xinjiang region of China. Curr Oncol. 2014; 21: e67-74.

Kang K, Nho CW, Kim ND, Song DG, Park YG, Kim M, Pan CH, Shin D, Oh SH, Oh HS. Daurinol, a catalytic inhibitor of topoisomerase II alpha, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase. Int J Oncol. 2014; 45: 558-66.

Lisik W, Tejpal N, Gong Y, Skelton TS, Ganachari M, Bremer EG, Kloc M, Ghobrial RM. Down regulation of genes involved in T cell polarity and motility during the induction of heart allograft tolerance by allochimeric MHC I. PLoS One. 2009; 4: e8020.

Liu J, Zhang H, Jia L, Sun H. Effects of Treg cells and IDO on human epithelial ovarian cancer cells under hypoxic conditions. Mol Med Rep. 2015; 11: 1708-14.

Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi Y, Zhu LC, Zhang SL, Iwamori M. Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep. 2010; 23: 833-41.

Lueg G, Gross CC, Lohmann H, Johnen A, Kemmling A, Deppe M, Groger J, Minnerup J, Wiendl H, Meuth SG, Duning T. Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging. 2015; 36: 81-89.

Mao HL, Pang Y, Zhang X, Yang F, Zheng J, Wang Y, Liu P. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo. Oncol Rep. 2013; 29: 515-22.

Meng CF, Su B, Li W. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells. Mol Med Rep. 2011; 4: 1273-78.

Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, Koba S, Thibodeau R, Nagase K, Simonson WT, Seo A, Koelle DM, Madeleine M, Bhatia S, Nakajima H, Sano S, Hardwick JS, Disis ML, Cleary MA, Becker JC, Nghiem P. Down-regulation of MHC-I expression is preva-lent but reversible in Merkel cell carcinoma. Cancer Immunol Res. 2014; 2: 1071-79.

Ramakrishna V, Ross MM, Petersson M, Gatlin CC, Lyons CE, Miller CL, Myers HE, McDaniel M, Karns LR, Kiessling R, Parmiani G, Flyer DC. Naturally occurring peptides associated with HLA-A2 in ovarian cancer cell lines identified by mass spectrometry are targets of HLA-A2-restricted cytotoxic T cells. Int Immunol. 2003; 15: 751-63.

Reynolds CJ, Jones C, Blohmke CJ, Darton TC, Goudet A, Sergeant R, Maillere B, Pollard AJ, Altmann DM, Boyton RJ. The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse HLA class II alleles. Immunology 2014; 143: 438-46.

Sanchez-Munoz A, Jurado JM, Perez-Ruiz E, Alba E. Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer. Clin Transl Oncol. 2009; 11: 329-31.

Weston C, Connor J. Evidence for the influence of the iron regulatory MHC class I molecule HFE on tumor progression in experimental models and clinical populations. Transl Oncogenomics. 2014; 6: 1-12.

Yang Z, Liu YI, Wei X, Zhou X, Gong C, Zhang T, Jin P, Xu S, Ma D, Gao Q. Co-targeting EGFR and autophagy impairs ovarian cancer cell survival during detachment from the ECM. Curr Cancer Drug Targets. 2015; 15: 215-26.

Downloads

Additional Files

Published

2015-07-01

How to Cite

Wang, J. Y., N. Zhang, X. Yang, D. Gao, L. Yin, and S. Ji. “MHC Class I-Presented Tumor Antigen Appraisable for T-Cell Responses Against Ovarian Cancer”. Bangladesh Journal of Pharmacology, vol. 10, no. 3, July 2015, pp. 524-8, doi:10.3329/bjp.v10i3.23076.

Issue

Vol. 10 No. 3 (2015)

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).